Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000719 · ClinicalTrials.gov registry record · NA

A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
96
Enrollment target
7
Study locations

NCT00000719: Completed NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000719 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 96 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000719, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
96 participants
Enrollment target
7
Study locations

Study Summary

To determine the long-term safety and tolerance of four alternating and two intermittent regimens of zidovudine ( AZT ) and 2',3'-dideoxycytidine ( zalcitabine; ddC ) in the treatment of patients with advanced HIV disease who have had to discontinue AZT because of true hematologic intolerance to standard reduced doses of AZT. AIDS is a serious infectious disease caused by a new family of retrovirus which is spread primarily through sexual contact and administration of blood or blood products. Individuals who are infected with HIV could therefore benefit from therapy with an effective anti-AIDS virus agent. AZT and ddC have both been tested as antiviral agents and their potentially beneficial effects may be limited by time- and dose-dependent toxicity. A combination regimen using shorter courses of AZT and ddC might therefore be able to sustain treatment without producing toxicity. In addition, since the two drugs exhibit their major toxicity on different organ systems, cumulative or additive toxicity would not be expected.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • DRUG Zalcitabine

Study Locations (7)

California

  • USC CRS - Los Angeles
  • Ucsd, Avrc Crs - San Diego

Illinois

  • Northwestern University CRS - Chicago
  • Rush Univ. Med. Ctr. ACTG CRS - Chicago

Florida

  • Univ. of Miami AIDS CRS - Miami

Louisiana

  • Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU - New Orleans

Minnesota

  • University of Minnesota, ACTU - Minneapolis

Trial Details

FieldValue
Enrollment Target 96 participants
Est. Completion 1995-02
Phase NA
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00000719 record still lists

NCT00000719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.

NCT00000719 lists 7 locations in 5 states (California, Illinois, Florida).

Frequently Asked Questions

What is clinical trial NCT00000719 about?

NCT00000719 is a clinical study titled "A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease". To determine the long-term safety and tolerance of four alternating and two intermittent regimens of zidovudine ( AZT ) and 2',3'-dideoxycytidine ( zalcitabine; ddC ) in the treatment of patients with advanced HIV disease who have had to discontinue AZT because of true hematologic intolerance to sta...

What is the current status of trial NCT00000719?

This trial is currently completed. It is a NA study. The enrollment target is 96 participants. Estimated completion is 1995-02.

What conditions does trial NCT00000719 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000719?

The interventions under investigation include: Zidovudine (DRUG), Zalcitabine (DRUG).

Who is sponsoring clinical trial NCT00000719?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000719 being conducted?

This trial has 7 study locations across California, Florida, Illinois, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000719's enrollment target sits among peer trials

96 279th of 542 higher than 262 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Related registry views

Source: ClinicalTrials.gov NCT00000719, the US trial registry maintained by the National Library of Medicine. NCT00000719 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.